RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
        • 주제분류
        • 발행연도
        • 작성언어
        • 저자
          펼치기

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        A Fast Estimation Method of Soil Discharged by an Earth Pressure Balanced Shield Machine

        Zhu Wen,Xuening Rong,Zhen Wang,Songtong Han,Ziming Xiong,Yehui Shi 대한토목학회 2021 KSCE JOURNAL OF CIVIL ENGINEERING Vol.25 No.6

        The soil discharged by an earth pressure balanced (EPB) shield machine reflects ground loss and controls surface settlement. In engineering, the discharge was mainly estimated by weighing the tunnelling spoil, however, human disturbance and information lag bring serious hidden security risks to tunnel construction. Through the analysis of conveying flow and force of screw conveyor, an energy model of interaction between screw conveyor and soil discharged was proposed and verified experimentally. Then, the energy model was combined with the discharge equation and the force balance equation, and a semi-analytical method to fast estimate the soil discharged of the EPB shield machine was proposed. Taking an EPB shield construction project as an example, according to the data of earth pressure, the torque and the rotation of the screw conveyor recorded by EPB shield machine, the real-time soil discharged of EPB shield machine can be accurately estimated. The mean absolute error (MAE) of this method is 3.177 × 103 kg compared with the measured weight of tunnelling spoil, which verifies the rationality of the method and provides a method for further effective evaluation and control of ground loss.

      • KCI등재

        Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

        Zhichao Liao,Feng Li,Chao Zhang,Lei Zhu,Yehui Shi,Gang Zhao,Xu Bai,Shafat Hassan,Xinyue Liu,Ting Li,Peipei Xing,Jun Zhao,Jin Zhang,Ruwei Xing,Sheng Teng,Yun Yang,Kexin Chen,Jilong Yang 생화학분자생물학회 2019 Experimental and molecular medicine Vol.51 No.-

        Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR- 2). We conducted a single-arm, nonrandomized phase II study (NCT03121846) to assess the efficacy and safety of apatinib in patients with stage IV sarcoma. We recruited 64 patients with stage IV sarcoma who had failed chemotherapy. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were progression-free survival rate (PFR), objective response rate (ORR), and disease control rate (DCR) at week 12. Treatment-related adverse effects (AEs) were evaluated. Fifty-nine patients were assessed for efficacy and 64 patients for AEs. The median PFS was 7.93 months. At 12 weeks, the PFR was 74%, the ORR was 16.95% (10/59), and the DCR was 86.44% (51/59). The final ORR was 15.25% (9/59) and the DCR was 57.63% (34/59). Notably, 22 patients (34.38%) who developed hypertension, hand-foot-skin reaction, or proteinuria had significantly longer OS than those without these AEs (18.20 vs. 10.73 months; P = 0.002). We conclude that apatinib is effective and well tolerated in patients with advanced sarcoma. The development of hypertension, hand-foot-skin reaction, or proteinuria may indicate a favorable prognosis, representing a novel finding in sarcoma patients.

      • The Monocot-Specific Receptor-like Kinase SDS2 Controls Cell Death and Immunity in Rice

        Fan, Jiangbo,Bai, Pengfei,Ning, Yuese,Wang, Jiyang,Shi, Xuetao,Xiong, Yehui,Zhang, Kai,He, Feng,Zhang, Chongyang,Wang, Ruyi,Meng, Xiangzong,Zhou, Jinggeng,Wang, Mo,Shirsekar, Gautam,Park, Chan Ho,Bell Elsevier 2018 Cell host & microbe Vol.23 No.4

        <P><B>Summary</B></P> <P>Programmed cell death (PCD) plays critical roles in plant immunity but must be regulated to prevent excessive damage. The E3 ubiquitin ligase SPL11 negatively regulates PCD and immunity in plants. We show that <I>S</I>PL11 cell-<I>d</I>eath <I>s</I>uppressor <I>2</I> (SDS2), an S-domain receptor-like kinase, positively regulates PCD and immunity in rice by engaging and regulating SPL11 and related kinases controlling defense responses. An <I>sds2</I> mutant shows reduced immune responses and enhanced susceptibility to the blast fungus <I>Magnaporthe oryzae</I>. Conversely, <I>SDS2</I> over-expression induces constitutive PCD accompanied by elevated immune responses and enhanced resistance to <I>M. oryzae</I>. SDS2 interacts with and phosphorylates SPL11, which in turn ubiquitinates SDS2, leading to its degradation. In addition, SDS2 interacts with related receptor-like cytoplasmic kinases, OsRLCK118/176, that positively regulate immunity by phosphorylating the NADPH oxidase OsRbohB to stimulate ROS production. Thus, a plasma membrane-resident protein complex consisting of SDS2, SPL11, and OsRLCK118/176 controls PCD and immunity in rice.</P> <P><B>Highlights</B></P> <P> <UL> <LI> The RLK SDS2 positively regulates plant cell death and immunity in rice </LI> <LI> SDS2 phosphorylates E3 ligase SPL11, which in turn ubiquitinates SDS2 for degradation </LI> <LI> SDS2 phosphorylates receptor-like cytoplasmic kinases RLCK118 </LI> <LI> RLCK118 interacts with and phosphorylates the NADPH oxidase OsRbohB </LI> </UL> </P> <P><B>Graphical Abstract</B></P> <P>[DISPLAY OMISSION]</P>

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼